CR10317A - "forma galenica divisible que permite una liberacion modificada del principio activo" - Google Patents

"forma galenica divisible que permite una liberacion modificada del principio activo"

Info

Publication number
CR10317A
CR10317A CR10317A CR10317A CR10317A CR 10317 A CR10317 A CR 10317A CR 10317 A CR10317 A CR 10317A CR 10317 A CR10317 A CR 10317A CR 10317 A CR10317 A CR 10317A
Authority
CR
Costa Rica
Prior art keywords
divisible
active principle
modified release
allows
galenic form
Prior art date
Application number
CR10317A
Other languages
English (en)
Inventor
Fonknechten Gilles
Genty Patrick
Pean Jean-Manuel
Wuthrich Patrik
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39796790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10317(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR10317A publication Critical patent/CR10317A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una forma galenica divisible de liberacion modificada de principio activo, donde la forma galenica no subdividida y una fraccion de dicha forma obtenida por subdivision tienen un perfil de disolucion identico. Medicamentos
CR10317A 2008-03-21 2008-09-24 "forma galenica divisible que permite una liberacion modificada del principio activo" CR10317A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801561A FR2928836B1 (fr) 2008-03-21 2008-03-21 Forme galenique secable permettant une liberation modifiee du principe actif

Publications (1)

Publication Number Publication Date
CR10317A true CR10317A (es) 2008-11-26

Family

ID=39796790

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10317A CR10317A (es) 2008-03-21 2008-09-24 "forma galenica divisible que permite una liberacion modificada del principio activo"
CR20140334A CR20140334A (es) 2008-03-21 2014-07-10 Forma galénica divisible que permite una liberación modificada del principio activo

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20140334A CR20140334A (es) 2008-03-21 2014-07-10 Forma galénica divisible que permite una liberación modificada del principio activo

Country Status (35)

Country Link
US (3) US20090238870A1 (es)
EP (2) EP2103302A1 (es)
JP (2) JP5231906B2 (es)
KR (3) KR20090101048A (es)
CN (1) CN101347414B (es)
AP (1) AP2729A (es)
AR (1) AR067993A1 (es)
AU (1) AU2008207680B8 (es)
CA (1) CA2629670C (es)
CL (1) CL2008002486A1 (es)
CO (1) CO6020017A1 (es)
CR (2) CR10317A (es)
CU (1) CU23970B1 (es)
EA (1) EA200801862A1 (es)
EC (1) ECSP088727A (es)
FR (1) FR2928836B1 (es)
GT (1) GT200800163A (es)
HN (1) HN2008001466A (es)
IL (1) IL193611A0 (es)
JO (1) JO3052B1 (es)
MA (1) MA31218B1 (es)
ME (1) ME01031B (es)
MX (1) MX2008011579A (es)
MY (1) MY150660A (es)
NI (1) NI200800256A (es)
NZ (1) NZ570715A (es)
PE (1) PE20090991A1 (es)
SA (1) SA08290555B1 (es)
SG (1) SG155819A1 (es)
SV (1) SV2008003023A (es)
TW (1) TWI396561B (es)
UA (1) UA86731C2 (es)
UY (1) UY31307A1 (es)
WO (1) WO2009125087A1 (es)
ZA (1) ZA200807354B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507047A (ja) 2005-09-09 2009-02-19 ラボファーム インコーポレイテッド 持続性薬物放出組成物
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN106892856A (zh) * 2017-02-06 2017-06-27 山东科源制药股份有限公司 一种格列齐特粗品重结晶的制备方法
MX2022011505A (es) * 2020-03-16 2022-10-07 Gruenenthal Gmbh Comprimido ranurado.

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH069375A (ja) * 1992-04-10 1994-01-18 Takeda Chem Ind Ltd 分割可能な連結錠剤
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
EP1039890B1 (en) * 1997-12-08 2004-03-17 Bristol-Myers Squibb Company Novel salts of metformin and method
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
JP2006052230A (ja) * 1998-04-03 2006-02-23 Kyowa Hakko Kogyo Co Ltd 分割錠剤及びプレススルーパック
JP3839065B2 (ja) * 1998-04-03 2006-11-01 協和醗酵工業株式会社 分割錠剤及びプレススルーパック
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
HRP20010700B1 (hr) * 1999-03-31 2011-01-31 Janssen Pharmaceutica N.V. Prezelatinizirani skrob u formulaciji s kontroliranim otpustanjem
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DE10117208A1 (de) * 2001-04-06 2002-10-10 Wolff Walsrode Ag Verfahren zur Herstellung von niederviskosen, wässrigen Celluloseetherlösungen
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
EP1741435A4 (en) * 2004-04-29 2009-11-11 Lotus Pharmaceutical Co Ltd ORAL VAPORS WITH MODIFIED RELEASE AND METHOD OF MANUFACTURING THEM
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
WO2006061697A1 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
MX2007012443A (es) * 2005-04-08 2007-12-13 Abbott Lab Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales.
JP5046501B2 (ja) * 2005-08-18 2012-10-10 帝人ファーマ株式会社 複数の薬物を分離して保持する錠剤
US9028867B2 (en) * 2005-08-18 2015-05-12 Teijin Pharma Limited Formulation having accurate dose-dividing function
JP2009507047A (ja) * 2005-09-09 2009-02-19 ラボファーム インコーポレイテッド 持続性薬物放出組成物
BRPI0616694B8 (pt) * 2005-09-29 2021-05-25 Novartis Ag processo para preparar comprimido farmacêutico com 80 e 96% em peso com base no peso seco de vildagliptina e metformina ou seus sais farmaceuticamente aceitáveis
JP5361188B2 (ja) * 2006-08-10 2013-12-04 武田薬品工業株式会社 医薬組成物
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤

Also Published As

Publication number Publication date
MA31218B1 (fr) 2010-03-01
KR20110112266A (ko) 2011-10-12
KR20150035829A (ko) 2015-04-07
JP2010209103A (ja) 2010-09-24
CN101347414B (zh) 2011-11-23
CA2629670A1 (fr) 2008-10-01
JP5231906B2 (ja) 2013-07-10
PE20090991A1 (es) 2009-07-18
CN101347414A (zh) 2009-01-21
AU2008207680B2 (en) 2010-04-22
HK1127280A1 (en) 2009-09-25
NZ570715A (en) 2010-10-29
BRPI0803631A2 (pt) 2011-03-29
FR2928836A1 (fr) 2009-09-25
SG155819A1 (en) 2009-10-29
CL2008002486A1 (es) 2008-12-26
IL193611A0 (en) 2009-08-03
WO2009125087A1 (fr) 2009-10-15
CO6020017A1 (es) 2009-03-31
KR101693189B1 (ko) 2017-01-05
AP2729A (en) 2013-08-31
MX2008011579A (es) 2009-09-21
UA86731C2 (ru) 2009-05-12
US20090238870A1 (en) 2009-09-24
CA2629670C (fr) 2012-04-17
SV2008003023A (es) 2010-07-29
CR20140334A (es) 2014-08-20
ECSP088727A (es) 2008-10-31
UY31307A1 (es) 2008-10-31
JO3052B1 (ar) 2017-03-15
EA200801862A1 (ru) 2009-10-30
GT200800163A (es) 2010-05-21
AU2008207680B8 (en) 2010-05-13
JP2009227651A (ja) 2009-10-08
TW200940109A (en) 2009-10-01
EP3025706A1 (fr) 2016-06-01
AR067993A1 (es) 2009-10-28
AU2008207680A1 (en) 2009-10-08
MY150660A (en) 2014-02-14
US20130295176A1 (en) 2013-11-07
TWI396561B (zh) 2013-05-21
AP2008004614A0 (en) 2008-10-31
FR2928836B1 (fr) 2011-08-26
ME01031B (me) 2012-10-20
SA08290555B1 (ar) 2011-07-20
KR20090101048A (ko) 2009-09-24
US20140221449A1 (en) 2014-08-07
CU20080179A7 (es) 2011-04-26
ZA200807354B (en) 2008-11-26
HN2008001466A (es) 2011-04-25
CU23970B1 (es) 2013-12-27
NI200800256A (es) 2010-02-11
EP2103302A1 (fr) 2009-09-23

Similar Documents

Publication Publication Date Title
CR10317A (es) "forma galenica divisible que permite una liberacion modificada del principio activo"
PT2435025T (pt) Administração, por via respiratória, de agentes activos
AR084057A1 (es) Composiciones para el cuidado de telas
IT1400982B1 (it) Collirio osmotico trans-epiteliale per la cura del cheratocono.
SI2755473T1 (sl) Paraziticidni sestavki, ki obsegajo izoksazolinsko učinkovino, postopki in uporabe le-teh
BRPI0820997A2 (pt) Comprimidos de desintegração oral compreendendo difenidramina.
CL2011002968A1 (es) Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion.
EP2475427A4 (en) ACTRIIB ANTAGONISTS, THEIR DOSAGE AND APPLICATIONS THEREOF
BR112014010708A2 (pt) pró-fármaco à base de polietilenoglicol de adrenomedulina e utilização do mesmo
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
IT1397781B1 (it) Placca di sintesi modulare ad angolo variabile, in particolare per osteotomia della pelvi, e strumento e metodo per l'applicazione di una placca siffatta.
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
RU2011135537A (ru) Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов
SMT201400168B (it) Composti di benzen.solfonammidi, loro procedimentodi sintesi e loro utilizzo in medicina
BRPI1014511A2 (pt) Desfolhante à base de thidiazuron e 1,2,4- triazinonas.
EP2150256A4 (en) LOCAL ACTIVE, SOFT ANTIANDROGENE
CL2009000904A1 (es) Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
CL2008001043A1 (es) Forma amorfa y cristalina de la oxima de la e-1-(4-((1r,2s,3r)-1,2,3,4-tetrahidroxibutil)-1h-imidazol-2-il)-etanona; composicion farmaceutica; y uso para tratar, controlar o prevenir una enfermedad o un trastorno autoinmune o inflamatorio.
PH12013501552A1 (en) Oral care compositions
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
ATE531715T1 (de) 1,3-dihydro-2h-pyrroloä3.2-büpyridin-2-onderiva e,deren herstellung und deren therapeutische verwendungen
EA201071412A1 (ru) Дронедарон для предотвращения кардиоверсии
CL2013001684A1 (es) Composicion farmaceutica de administracion oral que comprende alisporivir, un componente lipofilico, un tensoactivo y un componente hidrofilico.
CL2008000092A1 (es) Compuestos derivados de 3-cianopiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compustos; y su uso en el tratamiento del transtorno de la agregacion plaquetaria.
UY34189A (es) Mezclas fungicidas que comprenden isoxazol y otro ingrediente activo.